Case Report on Multiple Autologous TIL Therapy for Aggressive Mucosal Melanoma

A 2026 case report by Fenge Li details a clinical trial for a patient with aggressive stage IV nasal mucosal melanoma. The report describes the patient's treatment timeline, including three cycles of autologous tumor-infiltrating lymphocyte (TIL) therapy combined with immune checkpoint inhibitors, resulting in repeated partial and complete responses. The 13.4 KB document is available under a CC-BY-4.0 license on figshare.

Use Cases

• Analyze the timeline and outcomes of multiple TIL infusion cycles based on the detailed case narrative.
• Study immune response patterns based on the described peripheral blood cell subtyping and cytokine secretion data.
• Review the safety profile and adverse event management for repeated TIL therapies as described in the report.

Strengths

• Provides a detailed longitudinal case study of a heavily pretreated patient, including specific response timelines (PR at 6 weeks, CR at 12 weeks).
• Includes references to three registered clinical trials (NCT06697665, NCT05941936, NCT05971589).
• Document is openly licensed (CC-BY-4.0) for reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is limited to a single case report, representing a sample size of one.

Provenance

Source

figshare, authored by Fenge Li.

Collection Method

Clinical case report and literature review.

Time Range

Covers the treatment and monitoring timeline for a single patient case.

Freshness

Last updated 2026-04-23 12:00:26; freshness should be verified.

Geography

null